Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLEek: Upadacitinib and Elsubrutinib in SLE
NCT03978520Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 2 trial of elsubrutinib, upadacitinib in systemic lupus erythematosus (SLE), sponsored by AbbVie Inc.. Started Jul 2019; status: completed.
02
Drugs
elsubrutinibupadacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03978520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978520.